HK1247844A1 - 1-甲基-d-色氨酸的盐和前药 - Google Patents

1-甲基-d-色氨酸的盐和前药 Download PDF

Info

Publication number
HK1247844A1
HK1247844A1 HK18107413.4A HK18107413A HK1247844A1 HK 1247844 A1 HK1247844 A1 HK 1247844A1 HK 18107413 A HK18107413 A HK 18107413A HK 1247844 A1 HK1247844 A1 HK 1247844A1
Authority
HK
Hong Kong
Prior art keywords
acid
methyl
alkyl
tryptophan
group
Prior art date
Application number
HK18107413.4A
Other languages
English (en)
Chinese (zh)
Inventor
M.莫蒂诺
M．莫蒂諾
S.库马尔
F.贾普里
S．庫馬爾
J.瓦尔多
H．普特蒂里
F．賈普里
H.庄
J．瓦爾多
H．莊
Original Assignee
新联基因公司
新聯基因公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 新联基因公司, 新聯基因公司 filed Critical 新联基因公司
Publication of HK1247844A1 publication Critical patent/HK1247844A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/20—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK18107413.4A 2015-07-24 2016-06-02 1-甲基-d-色氨酸的盐和前药 HK1247844A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562196671P 2015-07-24 2015-07-24
US62/196,671 2015-07-24
US201662305748P 2016-03-09 2016-03-09
US62/305,748 2016-03-09
PCT/US2016/035391 WO2017019175A1 (en) 2015-07-24 2016-06-02 Salts and prodrugs of 1-methyl-d-tryptophan

Publications (1)

Publication Number Publication Date
HK1247844A1 true HK1247844A1 (zh) 2018-10-05

Family

ID=57836622

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18107413.4A HK1247844A1 (zh) 2015-07-24 2016-06-02 1-甲基-d-色氨酸的盐和前药
HK18107364.3A HK1247837A1 (zh) 2015-07-24 2016-06-02 1-甲基-d-色氨酸的盐和前药

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18107364.3A HK1247837A1 (zh) 2015-07-24 2016-06-02 1-甲基-d-色氨酸的盐和前药

Country Status (24)

Country Link
US (4) US9732035B2 (enExample)
EP (4) EP3324958B1 (enExample)
JP (4) JP6842429B2 (enExample)
KR (2) KR20180086300A (enExample)
CN (2) CN111004167B (enExample)
AU (1) AU2016298471C1 (enExample)
BR (1) BR112018000225A2 (enExample)
CA (3) CA3132620C (enExample)
CL (1) CL2018000082A1 (enExample)
CO (1) CO2017013724A2 (enExample)
CR (1) CR20180023A (enExample)
DO (1) DOP2018000011A (enExample)
EA (1) EA201792256A1 (enExample)
EC (1) ECSP18002561A (enExample)
ES (2) ES2894334T3 (enExample)
HK (2) HK1247844A1 (enExample)
IL (2) IL255625B (enExample)
MA (1) MA43294A1 (enExample)
MX (1) MX2018001014A (enExample)
NZ (1) NZ736978A (enExample)
PE (1) PE20180928A1 (enExample)
PH (1) PH12017502046A1 (enExample)
WO (1) WO2017019175A1 (enExample)
ZA (1) ZA201800208B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180023A (es) 2015-07-24 2018-03-20 Newlink Genetics Corp Sales y profármacos de 1-metil-d-triptofano
CN109400517A (zh) * 2017-08-17 2019-03-01 上海时莱生物技术有限公司 1-甲基-色氨酸类化合物及其制备方法和用途
WO2019055786A1 (en) * 2017-09-14 2019-03-21 Lankenau Institute For Medical Research METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
CN109646683A (zh) * 2019-02-27 2019-04-19 武汉理工大学 一种1-mt-羧甲基壳聚糖药物的制备方法
CN115135385B (zh) 2019-11-12 2024-05-10 纳米医疗有限公司 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法
CN116507341A (zh) 2020-09-10 2023-07-28 纳米医疗有限公司 用于治疗癌症的含有pd-1拮抗剂前药的调配和/或共同调配的脂质体组合物及其方法
KR20250029575A (ko) 2023-08-23 2025-03-05 한국과학기술원 카메라 시스템의 동적 환경에 강인한 자기 위치 추정 장치 및 그 방법

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US14139A (en) 1856-01-22 Method oe ventilating railroad-cabs
GB1330573A (en) 1970-09-12 1973-09-19 Ajinomoto Kk Optical resolution of dl-tryptophan derivatives
US4072691A (en) 1974-01-12 1978-02-07 Tanabe Seiyaku Co., Ltd. Process for the resolution of DL-6-chlorotryptophan
US5185157A (en) 1990-05-02 1993-02-09 Caston John C Treatment of refractory Eosinophilia-Myalgia Syndrome with L-tryptophan composition
WO1996011927A1 (en) 1994-10-12 1996-04-25 Abbott Laboratories Endothelin antagonists
WO1999029310A2 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
YU68102A (sh) * 2000-03-16 2006-01-16 F. Hoffmann-La Roche Ag. Derivati karboksilne kiseline kao ip antagonisti
ATE397606T1 (de) * 2001-06-05 2008-06-15 Lilly Icos Llc Pyrazino(1',2':1,6)-pyrido(3,4-b) indole-1,4- dionderivate
EP1613308A4 (en) 2003-03-27 2008-02-20 Lankenau Inst Medical Res CANCER TREATMENT METHODS
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
JO2625B1 (en) * 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
EP1707560A4 (en) 2003-12-25 2007-10-17 Kureha Corp HYDROXAMIC ACID DERIVATIVE AND THE DERIVATIVE INHIBITOR OF THE GENERATION OF AGE
WO2006122150A1 (en) 2005-05-10 2006-11-16 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
US7705022B2 (en) 2005-10-27 2010-04-27 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
JP5294874B2 (ja) 2005-12-20 2013-09-18 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロ環
EP1981534A4 (en) * 2006-01-07 2012-04-04 Med College Georgia Res Inst INDOLAMINE-2,3-DIOXYGENASE WAYS IN GENERATING REGULATORY T CELLS
CA2569204A1 (en) 2006-11-28 2008-05-28 Apotex Technologies Inc. Crystalline d-isoglutamyl-d-tryptophan and the mono ammonium salt of d-isoglutamyl-d-tryptophan
US20100055111A1 (en) 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
WO2008115804A1 (en) 2007-03-16 2008-09-25 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use thereof
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
ATE514671T1 (de) * 2008-02-01 2011-07-15 Firmenich & Cie Substituierte cyclohexenone
WO2009132238A2 (en) 2008-04-24 2009-10-29 Newlink Genetics Ido inhibitors
MX2011000235A (es) 2008-07-08 2011-02-23 Incyte Corp 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa.
MX363732B (es) 2009-05-13 2019-04-01 Gilead Pharmasset Llc Star Compuestos antivirales.
ES2601226T3 (es) * 2009-10-28 2017-02-14 Newlink Genetics Corporation Derivados de imidazol como inhibidores de IDO
US20130142815A1 (en) * 2010-02-09 2013-06-06 Georiga Health Sciences Univ. Research Inst., Inc. Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase
NO2694640T3 (enExample) 2011-04-15 2018-03-17
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
HK1215256A1 (zh) 2012-11-20 2016-08-19 Vertex Pharmaceuticals Incorporated 用作吲哚胺2，3-二氧化酶的抑制劑的化合物
EP2970173B1 (en) 2013-03-14 2018-05-09 Curadev Pharma Private Ltd. Inhibitors of the kynurenine pathway
CN105189466A (zh) 2013-03-14 2015-12-23 新联基因公司 作为色氨酸代谢介导的免疫抑制的抑制剂的三环化合物
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
SG11201506920QA (en) 2013-03-15 2015-09-29 Bristol Myers Squibb Co Ido inhibitors
EP2970155B1 (en) 2013-03-15 2018-04-25 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase (ido)
CN105473550B (zh) 2013-07-01 2019-02-15 百时美施贵宝公司 Ido抑制剂
ES2707961T3 (es) 2013-07-11 2019-04-08 Bristol Myers Squibb Co Inhibidores de IDO
CR20180023A (es) 2015-07-24 2018-03-20 Newlink Genetics Corp Sales y profármacos de 1-metil-d-triptofano
EP3426633A4 (en) 2016-03-09 2020-03-04 Emory University Elimination of hepatitis b virus with antiviral agents
US10741094B2 (en) 2016-06-30 2020-08-11 Timpson Electrical & Aerial Services, LLC High voltage training device and system and method thereof

Also Published As

Publication number Publication date
CR20180023A (es) 2018-03-20
CN107847486A (zh) 2018-03-27
US9732035B2 (en) 2017-08-15
CN111004167A (zh) 2020-04-14
KR20180086300A (ko) 2018-07-30
US20200283385A1 (en) 2020-09-10
AU2016298471B2 (en) 2019-08-22
CA3051388C (en) 2021-11-09
CA3132620A1 (en) 2017-02-02
MA43294A1 (fr) 2020-04-30
CL2018000082A1 (es) 2018-06-15
US10207990B2 (en) 2019-02-19
EP3954369B1 (en) 2025-08-20
US20180134658A1 (en) 2018-05-17
PH12017502046A1 (en) 2018-04-23
ES2894334T3 (es) 2022-02-14
US11485705B2 (en) 2022-11-01
ECSP18002561A (es) 2018-03-31
JP2023060349A (ja) 2023-04-27
EP3613420B1 (en) 2022-05-25
EA201792256A1 (ru) 2018-07-31
BR112018000225A2 (pt) 2018-09-04
NZ736978A (en) 2019-06-28
ES2923184T3 (es) 2022-09-26
EP3954369A1 (en) 2022-02-16
CN111004167B (zh) 2024-03-22
EP3324958A1 (en) 2018-05-30
IL255625A (en) 2018-01-31
JP7286299B2 (ja) 2023-06-05
CA3132620C (en) 2024-03-05
PE20180928A1 (es) 2018-06-08
MX2018001014A (es) 2018-05-23
CA3051388A1 (en) 2017-02-02
IL255625B (en) 2019-08-29
AU2016298471A1 (en) 2017-11-23
CO2017013724A2 (es) 2018-03-28
WO2017019175A1 (en) 2017-02-02
KR20180030825A (ko) 2018-03-26
EP3324958B1 (en) 2021-07-28
EP3954369C0 (en) 2025-08-20
AU2016298471C1 (en) 2020-03-05
JP6842429B2 (ja) 2021-03-17
CA2992016C (en) 2019-10-22
JP2019011381A (ja) 2019-01-24
JP2018522830A (ja) 2018-08-16
EP3613420A1 (en) 2020-02-26
EP4659747A2 (en) 2025-12-10
DOP2018000011A (es) 2018-04-30
HK1247837A1 (zh) 2018-10-05
US20170022157A1 (en) 2017-01-26
ZA201800208B (en) 2018-12-19
EP3324958A4 (en) 2018-10-24
US20190248739A1 (en) 2019-08-15
CA2992016A1 (en) 2017-02-02
IL268048A (en) 2019-09-26
JP2021121633A (ja) 2021-08-26

Similar Documents

Publication Publication Date Title
JP7286299B2 (ja) １－メチル－ｄ－トリプトファンの塩及びプロドラッグ
KR100816945B1 (ko) 선택적인 사이클린 의존성 키나제 4 억제제로서의이세싸이오네이트 염
CN101821255A (zh) 作为pi3k抑制剂的2-吗啉-4-基-嘧啶类化合物
CA2985859A1 (en) Tbk/ikk.epsilon. inhibitor compounds and uses thereof
KR20200130287A (ko) 헤테로아릴 화합물, 이의 약학 조성물 및 이의 치료적 용도
AU2022313345B2 (en) Anti-inflammatory coupling compound drug, and preparation method therefor and use thereof
EA040751B1 (ru) Соли и пролекарства 1-метил-d-триптофана